Table 1.
Clinical and demographic features of the diagnostic cohorts
| Con | AD | PD spectrum | bvFTD | ALS | CJD | |
|---|---|---|---|---|---|---|
| N | 75 | 73 | 26 | 18 | 20 | 22 |
| f/m | 45/30 | 47/26 | 11/15 | 9/9 | 8/12 | 14/8 |
| Age (years) | 69±13 | 70±8 | 70±8 | 68±10 | 64±13 | 65±8 |
| CSF VILIP-1 [pg/ml]a | 91 (72−119) | 154 (119−220) | 112 (62−166) | 105 (81−134) | 98 (64−141) | 624 (326−1173) |
| Serum VILIP-1 [pg/ml]b | 23 (18–31) | 33 (24–36) | 27 (18–32) | 28 (21–42) | 26 (20–46) | 96 (52–142) |
| CSF t-tau [pg/ml]c | 239 (159–307) | 689 (517–932) | 285 (152–325) | 331 (260–426) | 199 (141–337) | 8275 (4403–19,408) |
| CSF p-tau 181 | 49 (36–70) | 120 (94–148) | 49 (36–64) | 43 (27–57) | 37 (29–57) | N/A |
| CSF Abeta 1-42 [pg/ml]d | 985 (778–1255) | 487 (417–593) | 899 (517–1116) | 871 (735–1157) | 945 (786–1147) | N/A |
| MMSE | N/A | 23 (17–26) | 28 (23.5–29) | 26 (24–27) | N/A | N/A |
| CDR SOB | N/A | 3.5 (2–5) | 0.5 (0–2.5) | 3.75 (2.5–8.9) | N/A | N/A |
Age in mean±SD. For all other concentrations, the median and IQR are shown. aAD vs. Con and CJD vs. Con, PD spectrum, FTD, ALS p<0.0001. AD vs. ALS p=0.006, vs. PD spectrum p=0.0055, vs. FTD p=0.0032, vs. CJD p=0.0029. bAD vs. Con p=0.0057, CJD vs. Con, vs. AD, vs PD spectrum p<0.0001. CJD vs. FTD p=0.0002. CJD vs. ALS p=0.0004. cAD and CJD vs. all other groups p<0.0001. AD vs. CJD p=0.033. dAD vs. all other groups p<0.0001; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CDR SOB, clinical dementia rating sum of boxes; CJD, Creutzfeldt-Jakob disease; Con, non-neurodegenerative control; CSF, cerebrospinal fluid; f, female; FTD, frontotemporal dementia; IQR, interquartile range; m, male; MMSE, Mini-Mental State Examination; N/A, not applicable; PD, Parkinson’s disease